Calm Study - Sertraline Vs. Placebo in the Treatment of Anxiety in Children and Adolescents with Neurodevelopmental Disorders
We are conducting a study on a medication called sertraline, which could help reduce anxiety in children and teens (ages 8-17) with neurodevelopmental disorders who have anxiety. Sertraline, a SSRI, has intensive evidence to support its use in children's and youth with anxiety but not within neurodevelopmental disorders.
Who can participate?
Who can participate?
- Children and teens between 8 and 17 years old
- Diagnosed with autism spectrum disorder (ASD), ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.
- Meet criteria for an anxiety disorder
- Able to tolerate venipuncture (bloodwork)
- This study is comparing sertraline against placebo for reducing anxiety symptoms
- The trial is 16 weeks long
- There are 7 study visits (mix of online and in person)
- Study procedures includes bloodwork, wearing smartwatch technology, and questionnaires.
- Parking will be covered along with a gift card at each visit as a token of appreciation for your time and effort
- Sertraline may help improve anxiety symptoms in children and adolescents
- This research will help other children and families with neurodevelopmental disorders
- The most common side effect is headache, nausea, and dry mouth
- Email us at Metcoord@UAlberta.ca or phone/leave a message 780-492-9461
Metformin Drug Trial for Patients with Fragile X Syndrome
We conducted a study to test the safety and benefits of Metformin, a drug given to patient with diabetes, on patients with Fragile X. Metformin has been shown to improve some difficulties and symptoms of people with the syndrome, including over-eating, obesity, hypogonadism, learning/cognition delays, and delayed puberty.
This study will be a double-blind, placebo controlled trial. We are currently not recruiting anymore!
For those interested in the results of this study, please email us at Metcoord@UAlberta.ca to sign up for our webinar this summer or a link to the paper when it is released.
This study will be a double-blind, placebo controlled trial. We are currently not recruiting anymore!
For those interested in the results of this study, please email us at Metcoord@UAlberta.ca to sign up for our webinar this summer or a link to the paper when it is released.